(EVK) Evonik Industries - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000EVNK013

Specialty Additives, Nutrition Care, Smart Materials, Technology Infrastructure

Stock: Specialty Chemicals
Age -

MCap 7,063m
Avg Vol 1.01M (13.3M EUR)

Beta 0.239
Volatility 25.08%

EPS (Earnings per Share)

EPS CAGR: -36.64%
EPS Trend: -39.6%

Last SUE: -0.97
Qual. Beats: 0

Revenue

Rev. CAGR: -4.88%
Rev. Trend: -82.3%

Last SUE: -0.53
Qual. Beats: 0

Dividends

Dividend Yield	6.14%
Yield on Cost 5y	5.71%
Yield CAGR 5y	0.43%
Payout Consistency	96.5%
Payout Ratio	86.0%

Risk via 5d forecast
Volatility	25.1%
Value at Risk 5%th	40.3%
Relative Tail Risk	-2.40%

Reward TTM
Sharpe Ratio	-1.08
Alpha	-31.28
CAGR/Max DD	-0.26

Character TTM
Hurst Exponent	0.419
Beta	0.239
Beta Downside	0.412

Drawdowns 3y
Max DD	39.76%
Mean DD	12.42%
Median DD	10.71%

Description: EVK Evonik Industries January 07, 2026

Evonik Industries AG (XETRA:EVK) is a global specialty chemicals producer headquartered in Essen, Germany, operating across four business segments: Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure. The company supplies a wide range of high-performance chemicals-from polyurethane foam additives and curing agents for coatings to amino acids for animal nutrition and biocompatible materials for medical devices-serving markets in Asia-Pacific, Europe, the Middle East, Africa, the Americas, and beyond.

Key recent metrics: FY 2023 revenue reached €15.2 billion, with an adjusted EBITDA margin of roughly 14%, reflecting strong pricing power in the Specialty Additives and Smart Materials divisions. Growth is being driven by secular trends such as the automotive sector’s shift toward lightweight, fuel-efficient vehicles (boosting demand for polyamide 12 and specialty polymers) and the broader industrial push for decarbonisation, which fuels sales of high-efficiency additives and digital process-optimization services. The Nutrition & Care segment benefits from rising global protein demand, supporting higher volumes of methionine and lysine for animal feed.

For a deeper quantitative assessment, consider reviewing ValueRay’s detailed EVK valuation model.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (95.0m TTM) > 0 and > 6% of Revenue (6% = 856.0m TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -3.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 13.02% (prev 10.46%; Δ 2.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.22b > Net Income 95.0m (YES >=105%, WARN >=100%)

Net Debt (4.04b) to EBITDA (1.78b) ratio: 2.27 <= 3.0 (WARN <= 3.5)

Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (466.0m) change vs 12m ago 0.30% (target <= -2.0% for YES)

Gross Margin 22.56% (prev 25.25%; Δ -2.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 74.87% (prev 77.51%; Δ -2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.21 (EBITDA TTM 1.78b / Interest Expense TTM 217.0m) >= 6 (WARN >= 3)

Altman Z'' 2.87

(A) 0.10 = (Total Current Assets 5.30b - Total Current Liabilities 3.45b) / Total Assets 18.55b

(B) 0.40 = Retained Earnings (Balance) 7.41b / Total Assets 18.55b

(D) 0.71 = Book Value of Equity 7.18b / Total Liabilities 10.13b

Total Rating: 2.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.61

1. Piotroski 3.0pt

2. FCF Yield 4.04%

3. FCF Margin 2.87%

4. Debt/Equity 0.54

5. Debt/Ebitda 2.27

6. ROIC - WACC (= -1.51)%

7. RoE 1.08%

8. Rev. Trend -82.32%

9. EPS Trend -39.59%

What is the price of EVK shares?

As of January 21, 2026, the stock is trading at EUR 12.62 with a total of 1,050,701 shares traded.
Over the past week, the price has changed by -3.96%, over one month by -4.03%, over three months by -15.53% and over the past year by -24.36%.

Is EVK a buy, sell or hold?

Evonik Industries has no consensus analysts rating.

What are the forecasts/targets for the EVK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	14.9	18%
Analysts Target Price	-	-
ValueRay Target Price	12.7	0.6%

EVK Fundamental Data Overview January 19, 2026

Market Cap USD = 7.06b (6.08b EUR * 1.1624 EUR.USD)
P/E Trailing = 62.0952
P/E Forward = 19.9203
P/S = 0.426
P/B = 0.7278
P/EG = 5.0637
Revenue TTM = 14.27b EUR
EBIT TTM = 480.0m EUR
EBITDA TTM = 1.78b EUR
Long Term Debt = 3.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 830.0m EUR (from shortTermDebt, last quarter)
Debt = 4.49b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.04b EUR (from netDebt column, last quarter)
Enterprise Value = 10.12b EUR (6.08b + Debt 4.49b - CCE 454.0m)
Interest Coverage Ratio = 2.21 (Ebit TTM 480.0m / Interest Expense TTM 217.0m)
EV/FCF = 24.73x (Enterprise Value 10.12b / FCF TTM 409.0m)
FCF Yield = 4.04% (FCF TTM 409.0m / Enterprise Value 10.12b)
FCF Margin = 2.87% (FCF TTM 409.0m / Revenue TTM 14.27b)
Net Margin = 0.67% (Net Income TTM 95.0m / Revenue TTM 14.27b)
Gross Margin = 22.56% ((Revenue TTM 14.27b - Cost of Revenue TTM 11.05b) / Revenue TTM)
Gross Margin QoQ = 18.17% (prev 26.61%)
Tobins Q-Ratio = 0.55 (Enterprise Value 10.12b / Total Assets 18.55b)
Interest Expense / Debt = 1.25% (Interest Expense 56.0m / Debt 4.49b)
Taxrate = 44.70% (194.0m / 434.0m)
NOPAT = 265.4m (EBIT 480.0m * (1 - 44.70%))
Current Ratio = 1.54 (Total Current Assets 5.30b / Total Current Liabilities 3.45b)
Debt / Equity = 0.54 (Debt 4.49b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.27 (Net Debt 4.04b / EBITDA 1.78b)
Debt / FCF = 9.88 (Net Debt 4.04b / FCF TTM 409.0m)
Total Stockholder Equity = 8.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.50% (Net Income 95.0m / Total Assets 18.55b)
RoE = 1.08% (Net Income TTM 95.0m / Total Stockholder Equity 8.76b)
RoCE = 3.86% (EBIT 480.0m / Capital Employed (Equity 8.76b + L.T.Debt 3.66b))
RoIC = 2.69% (NOPAT 265.4m / Invested Capital 9.85b)
WACC = 4.20% (E(6.08b)/V(10.57b) * Re(6.80%) + D(4.49b)/V(10.57b) * Rd(1.25%) * (1-Tc(0.45)))
Discount Rate = 6.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 86.56% ; FCFF base≈706.6m ; Y1≈723.0m ; Y5≈801.6m
Fair Price DCF = 42.51 (EV 23.85b - Net Debt 4.04b = Equity 19.81b / Shares 466.0m; r=5.90% [WACC]; 5y FCF grow 2.21% → 2.90% )
EPS Correlation: -39.59 | EPS CAGR: -36.64% | SUE: -0.97 | # QB: 0
Revenue Correlation: -82.32 | Revenue CAGR: -4.88% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.32 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.16 | Chg30d=-0.075 | Revisions Net=-5 | Growth EPS=-7.5% | Growth Revenue=-0.2%

Additional Sources for EVK Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle